Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        121-132 of 167 results for 'fiona stanley'

        Refine research

        Research

        Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody test

        Peter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group which sits in the Wesfarmers Centre of Vaccines and Infectious Diseases. Professor Richmond is a ...

        Research

        Serological Responses to Streptococcus pyogenes Vaccine Candidate Antigens Suggests That Streptococcus dysgalactiae Is the Predominant Cause of Lower Limb Cellulitis

        A future Streptococcus pyogenes (Strep A) vaccine will ideally prevent a significant burden of lower limb cellulitis; however, natural immune responses to proposed vaccine antigens following an episode of cellulitis remain uncharacterized. ...

        Research

        Patient preferences for prophylactic regimens requiring regular injections in children and adolescents: A systematic review and thematic analysis

        At present, limited literature exists exploring patient preferences for prophylactic treatment of acute rheumatic fever and rheumatic heart disease. Given low treatment completion rates to this treatment in Australia, where the burden of disease predominantly affects Aboriginal and Torres Strait Islander people, an improved understanding of factors driving patient preference is required to improve outcomes. ...

        Research

        Wellbeing study

        Helen Alix Fiona Nicole Elmie Lisa Rigel Milroy Woolard Wood Wickens Janse Van Rensburg McGivern Paciente HM AW FW NW EJVR LM RP MBBS; FRANZCP; CATCAP BPsych (Hons), PhD BHlthSc (Hons) BA, BSc BA (Hons 1, Psych) MPH (Applied Public Health and Public ...

        Research

        Ultra-short course, high-dose primaquine to prevent Plasmodium vivax infection following uncomplicated pediatric malaria: A randomized, open-label, non-inferiority trial of early versus delayed treatment

        We aimed to assess safety, tolerability, and Plasmodium vivax relapse rates of ultra-short course (3.5 days) high-dose (1 mg/kg twice daily) primaquine (PQ) for uncomplicated malaria because of any Plasmodium species in children randomized to early- or delayed treatment. ...

        Research

        Could late-latent syphilis be treated with a single subcutaneous infusion of long-acting penicillin?

        Syphilis is an important global health threat and little has changed in its treatment since the mid-20th century. For late-latent or syphilis infection of unknown duration, the standard treatment of multiple intramuscular injections of benzathine penicillin G (BPG) are associated with significant pain and distress to clients and caregivers, negatively impacting on treatment completion. ...

        Research

        FeBRILe3– Fever, Blood cultures and Readiness for discharge in Infants Less than 3 months’ old

        Tom Snelling T BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@telethonkids.org.au Head, Infectious Disease Implementation Research Professor Tom Snelling is Head of the Infectious Disease ...

        Research

        Paediatric post-grommets surgery review: Audiology-led clinic

        Otitis media has a high prevalence in childhood, and grommet insertion is the most common surgical treatment for OM. The public health system in Australia faces considerable strains, including high demand for Ear, Nose and Throat specialists. Extending the scope of practice for audiologists to manage post-operative care for children receiving grommets has the potential to alleviate this burden. ...

        Research

        Short-course, high-dose primaquine regimens for the treatment of liver-stage vivax malaria in children

        To assess the pharmacokinetics, safety, and tolerability of two high-dose, short-course primaquine (PQ) regimens compared with standard care in children with Plasmodium vivax infections. ...

        Research

        Factors influencing scar formation following Bacille Calmette-Guérin (BCG) vaccination

        The prevalence of scar formation following Bacille Calmette-Guérin (BCG) vaccination varies globally. The beneficial off-target effects of BCG are proposed to be stronger amongst children who develop a BCG scar. Within an international randomised trial ('BCG vaccination to reduce the impact of coronavirus disease 2019 (COVID-19) in healthcare workers'; BRACE Trial), this nested prospective cohort study assessed the prevalence of and factors influencing scar formation, as well as participant perception of BCG scarring 12 months following vaccination. ...

        Research

        Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial

        Recurrences of herpes simplex virus (HSV) in the orofacial region (herpes labialis or cold sores) impact quality-of-life. We aimed to study whether the bacille Calmette-Guérin (BCG) vaccine can attenuate cold sore recurrences through off-target immunomodulatory effects. ...

        Research

        Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial

        Bacille Calmette-Guérin (BCG) vaccination has off-target (non-specific) effects that are associated with protection against unrelated infections and decreased all-cause mortality in infants. We aimed to determine whether BCG vaccination prevents febrile and respiratory infections in adults. ...

        Page 11 of 14